Senti Biosciences Inc (SNTI)
Senti Biosciences, Inc. is a clinical-stage biotechnology company listed on NASDAQ under the ticker SNTI. The company focuses on cell and gene therapy programs built around its gene circuit platform, with an emphasis on engineered cell therapies for serious diseases. Its pipeline includes SENTI-202, an off-the-shelf CAR-NK therapy being developed for blood cancers and relapsed or refractory hematologic malignancies, including acute myeloid leukemia, and SENTI-301A, an off-the-shelf CAR-NK therapy under development for solid tumors and hepatocellular carcinoma. Senti Biosciences also works on a paired antigen discovery platform used to identify and validate tumor-related targets, alongside additional preclinical and partnered programs in gene therapy, cell therapy, and regenerative medicine. The company was incorporated in 2016 and is based in South San Francisco, California.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-SNTI
|
$0.39
|
-18.7% Downside
|
Overvalued
|
$13 2,628.2% Upside
|
—
|
Bargain
|
Weak
|
—
|
—
|
—
|
0.0%
|
August 18, 2026
|
-0.3x
|
5.8x
|
390.5x
|
13.511 M
|
24.854 M
|
58.6%
|
40.0%
|
-17.8
|
—
|
71.9%
|
